ERBB2 and breast cancer: BiKe and TriKE specific for HER2 or EpCam were developed for BC, and, during the revision of this paper, GT Biopharma announced the initiation of clinical development of TriKE therapy for the treatment of HER2+ breast and gastrointestinal cancers, using a tri-specific scFv recombinant fusion protein conjugate composed of anti-CD16 and anti-HER2 antibodies, and a modified form of IL-15 (61).